Evidence map›Paper›PMID 38716485›Full record

ArticleActa oncologica (Stockholm, Sweden)2024

TNM stage in the Nordic Cancer Registries 2004-2016: Registration and availability.

Gerda Engholm, Frida E Lundberg, Simon M Kønig, Elínborg Ólafsdóttir, Tom B Johannesen, David Pettersson, Nea Malila, Lina S Mørch, Anna L.V. Johansson, Søren Friis

Abstract read
In one paragraph

Article in Acta oncologica (Stockholm, Sweden), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Platelet-to-lymphocyte ratio and systemic inflammation response index are the optimal combination for risk stratification in patients with nasopharyngeal carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Enhancing TNM Stage Completeness Using the SEER Summary Stage: A Nationwide Study From Korea.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2025
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gerda EngholmDanish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark. gerda@cancer.dk.
Frida E LundbergDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Simon M KønigDanish Cancer Institute, Cancer Epidemiology and Surveillance, Danish Cancer Society, Copenhagen, Denmark.
Elínborg ÓlafsdóttirIcelandic Cancer Registry, Reykjavik, Iceland.
Tom B JohannesenCancer Registry of Norway, Oslo, Norway.
David PetterssonSwedish Cancer Registry, National Board of Health and Welfare, Stockholm, Sweden.
Nea MalilaFinnish Cancer Registry, Helsinki, Finland.
Lina S MørchDanish Cancer Institute, Cancer and Medicine, Danish Cancer Society, Copenhagen, Denmark.
Anna L.V. JohanssonDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Cancer Registry of Norway, Oslo, Norway.
Søren FriisDanish Cancer Institute, Cancer Epidemiology and Surveillance, Danish Cancer Society, Copenhagen, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeStage at cancer diagnosis is an important predictor of cancer survival. TNM stage is constructed for anatomic solid cancer diagnoses from tumor size (T), nodal spread (N) and distant metastasis (M) and categorized in groups 0-I, II, II and IV. TNM stage is imperative in cancer diagnosis, management and control, and of high value in cancer surveillance, for example, monitoring of stage distributions. This study yields an overview of TNM availability and trends in stage distribution in the Nordic countries for future use in monitoring and epidemiologic studies. MATERIAL AND

methodsTNM information was acquired from the cancer registries in Denmark, Norway, Sweden, and Iceland during 2004-2016 for 26 cancer sites in the three former countries and four in Iceland. We studied availability, comparability, and distribution of TNM stage in three periods: 2004-2008, 2009-2013, and 2014-2016, applying a previously validated algorithm of 'N0M0 for NXMX'. For cancers of colon, rectum, lung, breast, and kidney, we examined TNM stage-specific 1-year relative survival to evaluate the quality in registration of TNM between countries.

resultsDenmark, Sweden, and Iceland exhibited available TNM stage proportions of 75-95% while proportions were lower in Norway. Proportions increased in Sweden over time but decreased in Denmark. One-year relative survival differed substantially more between TNM stages than between countries emphasizing that TNM stage is an important predictor for survival and that stage recording is performed similarly in the Nordic countries.

interpretationAssessment and registration of TNM stage is an imperative tool in evaluations of trends in cancer survival between the Nordic countries.

Indexed as

NeoplasmsNeoplasm StagingRegistriesDenmarkFemaleHumansIcelandMaleNorwayScandinavian and Nordic CountriesSweden

Identifiers

PMID38716485
PMCPMC11332511

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.